Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reauthorising US FDA user fees: a slow-moving train wreck?

This article was originally published in SRA

Executive Summary

Failure by Congress to secure the timely reauthorisation of critical drug and device user fee programmes will mean trouble for the Food and Drug Administration, industry and patients, warns Steven Grossman.

You may also be interested in...

President Obama, please retain Commissioner Hamburg

With the re-election of President Obama in the US, many people are sitting back and assuming that the Food and Drug Administration won’t change much. It doesn’t need to: Commissioner Margaret Hamburg is doing a good job; the agency is moving forward to improve food, drug and device safety; more rational and predictable review processes are being implemented; and there are at least three relatively new laws that need ongoing attention.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts